001025640 001__ 1025640
001025640 005__ 20250203103258.0
001025640 0247_ $$2doi$$a10.1016/j.parkreldis.2023.105488
001025640 0247_ $$2ISSN$$a1353-8020
001025640 0247_ $$2ISSN$$a1873-5126
001025640 0247_ $$2pmid$$a37407343
001025640 0247_ $$2WOS$$aWOS:001078735000001
001025640 037__ $$aFZJ-2024-03029
001025640 082__ $$a610
001025640 1001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b0$$eCorresponding author
001025640 245__ $$aNeuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development
001025640 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
001025640 3367_ $$2DRIVER$$aarticle
001025640 3367_ $$2DataCite$$aOutput Types/Journal article
001025640 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1714732126_29383
001025640 3367_ $$2BibTeX$$aARTICLE
001025640 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001025640 3367_ $$00$$2EndNote$$aJournal Article
001025640 520__ $$aBackgroundA critical challenge for Huntington's disease (HD) clinical trials in disease modification is the definition of endpoints that can capture change when clinical signs are subtle/non-existent. Reliable biomarkers are therefore urgently needed to facilitate drug development by allowing the enrichment of clinical trial populations and providing measures of benefit that can support the establishment of efficacy.MethodsBy systematically examining the published literature on HD neuroimaging biomarker studies, we sought to advance knowledge to guide the validation of neuroimaging biomarkers. We started by reviewing both cross-sectional and longitudinal studies and then conducted an in-depth review to make quantitative comparisons between biomarkers using data only from longitudinal studies with samples sizes larger than ten participants in PET studies or 30 participants in MRI studies.ResultsFrom a total of 2202 publications initially identified, we included 32 studies, 19 of which underwent in-depth comparative review. The majority of included studies used various MRI-based methods (manual to automatic) to longitudinally assess either the volume of the putamen or the caudate, which have been shown to undergo significant structural change during HD natural history.ConclusionDespite the impressively large number of neuroimaging biomarker studies, only a small number of adequately designed studies met our criteria. Among these various biomarkers, MRI-based volumetric analyses of the caudate and putamen are currently the best validated for use in the disease phase before clinical motor diagnosis. A biomarker that can be used to demonstrate a disease-modifying effect is still missing.
001025640 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001025640 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x1
001025640 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001025640 7001_ $$0P:(DE-Juel1)178805$$aGiehl, Kathrin$$b1
001025640 7001_ $$aReetz, Kathrin$$b2
001025640 7001_ $$aSampaio, Cristina$$b3
001025640 7001_ $$aMestre, Tiago A.$$b4
001025640 773__ $$0PERI:(DE-600)2027635-7$$a10.1016/j.parkreldis.2023.105488$$gVol. 114, p. 105488 -$$p105488 -$$tParkinsonism & related disorders$$v114$$x1353-8020$$y2023
001025640 909CO $$ooai:juser.fz-juelich.de:1025640$$pVDB
001025640 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)169110$$aForschungszentrum Jülich$$b0$$kFZJ
001025640 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)178805$$aForschungszentrum Jülich$$b1$$kFZJ
001025640 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001025640 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
001025640 9141_ $$y2024
001025640 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2022$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
001025640 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-24
001025640 920__ $$lyes
001025640 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
001025640 980__ $$ajournal
001025640 980__ $$aVDB
001025640 980__ $$aI:(DE-Juel1)INM-2-20090406
001025640 980__ $$aUNRESTRICTED